Business
U.S. Approval and Issuance of CDX Antibody Patent
U.S. Approval and Issuance of CDX Antibody Patent.
About this update from Hemogenyx Pharmaceuticals Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 6330A\n Hemogenyx Pharmaceuticals PLC\n 02 June 2021\n \n \n \n \n 2 June 2021\n \n \n Hemogenyx Pharmaceuticals plc\n \n (\"Hemogenyx Pharmaceuticals\" or the \"Company\")\n \n U.S. Approval and Issuance of CDX Antibody Patent\n \n \n \n Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce that a patent application entitled METHOD OF ELIMINATING HEMATOPOIETIC STEM CELLS/HEMATOPOIETIC PROGENITORS (HSC/HP) IN A PATIENT USING BI-SPECIFIC ANTIBODIES has been approved and issued by the United States Patent and Trademark Office. The patent was issued as Patent Number US 11,021,536 B2 (https://tinyurl.com/yspjv89w).\n \n This patent covers a method of use of a bi-specific antibody (\"CDX\"), one of the Company's original and lead product candidates, for conditioning bone marrow/hematopoietic stem cell (\"BM/HSC\") transplantation. It also covers a composition of matter (a subset of sequences) of monoclonal antibodies against target proteins existing on the surface of hematopoietic stem cells/hematopoietic progenitors (\"HSC/HP\"), and/or a number of leukemias such as acute myeloid leukemia (\"AML\") as well as a protein that exists on the surface of immune cells (T cells).\n \n The method described in the patent (the \"Method\") was invented by Dr Vladislav Sandler, CEO and Co-founder of Hemogenyx Pharmaceuticals, working alone, and was then further developed and refined together with the Company's team of scientists in its laboratory facilities in New York City. The patent provides a method for preparing or conditioning of BM/HSC transplantation in lieu of the traditional conditioning protocol involving chemotherapy, which is highly toxic. The Method provides a recombinant single chain bi-specific antibody that binds to both human FMS-like tyrosine kinase 3 (FLT3) on the surface of \"unwanted cells\" and human CD3 on the surface of T cells, and the administering of a therapeutic amount of a pharmaceutical composition comprising the bi-specific antibody to the patient.\n \n If fully and successfully developed, the Method would obviate the need for highly toxic conditioning protocols, including chemotherapy, in patients who require BM/HSC transplantatio...